Here are 5 ASX biotechs expecting clinical trial results in the next few months!

Here are 5 ASX biotechs expecting clinical trial results in the next few months!

Dimerix (ASX:DXB)

Dimerix is in the middle of a Phase III trial or its DMX-200 drug for a condition known as Focal Segmental Glomerulosclerosis (FSGS). For patients with FSGS, the kidneys’ ability to purify (clean) the blood is impaired. This can lead to kidney failure that may eventually requires dialysis or a kidney transplant.

Dimerix expects full results in the next few months and this could lead to FDA approval. It will be the only approved therapy for FSGS for some time and has potential to make a lot of money. This is for several reasons most notoriously the global incidence rate – 7 per every 1 million people. But also, it has multiple licensing agreements for several jurisdictions includng the US as well as the EU, Japan, Canada, Japan and GCC countries. China remains unlicensed, but the company is working on securing a deal.

Also eep in mind that America’s Medicare Drug Price Negotiation Program exempts orphan drugs that treat ‘only one rare disease or condition’ from drug price negotiations. Other drugs targeting rare kidney diseases can attract price tags of several thousands of dollars per month.

Chimeric Therapeutics (ASX:CHM)

This company specialises in CAR-T therapy and has 4 Phase 1 trials under 3 FDA INDs. The biggest is a Phase 1/2 trial using CHM CDH17, utilising UPenn Technology. The other 3 are Phase 1b trials, 2 into an off the shelf NK therapy at Cape Western Reserve University and the other one using technology from the City of Hope.

Preliminary results from the first of these trials have shown promising results with dose levels being safe. And so the company is increasing dosage from 50 million CDH17 CAR-T cells to 150 million. We can expect to see results flow over the next few months.

Actinogen (ASX:ACW)

Actinogen is the only ASX company battling Alzheimers and has had a turbulant history. All biotechs can be turbulant given the difficulty of battling diseases, but neurodegenerative diseases are particularly difficult. Actinogen first bought Xanamem out of the University of Edinburgh in 2014 and has been working on it ever since, even in spite of encountering multiple setbacks along the way.

But it is currently in a Phase 2b/3 trial with over 200 patients. Initial results from an interim analysis triggered by the 100th patient reaching 24 weeks of treatment are anticipated in January 2026, and the final set of results by the end of the calendar year.

Blinklab (ASX:BB1)

Blinklab is developing an e-platform that can help diagnose neurological disorders in children such as ADHD and autism. The device consists of a mobile app to collect Data and a Portal to analyse the data and to customise the tests.

Keep in mind that this is a specific check for these conditions as opposed to a general subjective judgement. It will certainly be cheaper than the typical $1-5k cost for a typical evaluation. The test makes a judgement by biomarker detections, evaluating brain function, computer vision and facial reflexes in response to visual and auditory stimuli.

The company is commencing a 520-patient study which it hopes to obtain results from in Q2 of nerxt year and submit its case to the FDA shortly thereafter – it normally takes 90 days to get a decision, but it can take quicker (or longer).

Cynata (ASX:CYP)

Cynata is one of the few ASX specialists in stem cell therapy, using a technology called MSCs. It has four clinical programs right now. One of these, Diabetic Foot Ulcers is in limbo, and the remaining 3 are osteoarthritis, Gravts vs Host Disease and Kidney Transplantation. The company has Phase 3 results for osteoarthritis due in February-April 2026, Phase 2 for Graft vs Host in H1 of 2026 and results from Cohort 1 of a Phase 1/2 trial for kidney transplantation in Q4 of 2025.

Inevitably, it is the osteoarthritis program that is most intriguing because it is such a burden and because there are no treatment options that specifically address cartilage degradation. Cynata is in a Phase 2 study with 320 people, being managed by the University of Sydney, and this could well be a pivotal trial (i.e. the last one before regulatory approval).

What are the Best ASX Life Sciences Stocks to invest in right now?

Check our buy/sell tips